Aardvark Therapeutics (AARD) Cash from Financing Activities (2024 - 2026)
Aardvark Therapeutics (AARD) reported Cash from Financing Activities of $4000.0 for Q1 2026, down 100.0% on a YoY basis from $88.9 million in Q1 2025, and down 98.54% sequentially from $274000.0 in Q4 2025.
Aardvark Therapeutics (AARD) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 3 years of Cash from Financing Activities data on file, last reported at $4000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 100.0% year-over-year to $4000.0; the trailing twelve-month figure through Mar 2026 stood at $378000.0 (down 99.78% YoY), and the FY2025 full-year result was $89.2 million, up 8.85% from the prior year.
- Cash from Financing Activities fell to $4000.0 in Q1 2026, from $274000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $88.9 million in Q1 2025 to a low of -$1.0 million in Q4 2024.
- A 3-year average of $21.4 million and a median of $117500.0 in 2024 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 167.19% in 2025, while the deepest fall reached 100.09% in 2025.
- Tracing AARD's Cash from Financing Activities over 3 years: stood at -$1.0 million in 2024, then jumped by 127.02% to $274000.0 in 2025, then tumbled by 98.54% to $4000.0 in 2026.
- Business Quant data shows AARD's Cash from Financing Activities at $4000.0 in Q1 2026, $274000.0 in Q4 2025, and $171000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | 4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | 274,000.00 |
| Dec 31, 2025 | 274,000.00 |
| Sep 30, 2025 | 171,000.00 |
| Sep 30, 2025 | 171,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Mar 31, 2025 | 88.88 Mn |
| Mar 31, 2025 | 88.88 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | 64,000.00 |
| Sep 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 82.94 Mn |
| Jun 30, 2024 | 82.94 Mn |